Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Koninklijke Philips NV is the Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.

  • Revenue in EUR (TTM)17.35bn
  • Net income in EUR-1.36bn
  • Incorporated2000
  • Employees79.10k
  • Location
    Royal PhilipsHigh Tech Campus 52EINDHOVEN 5656 AGNetherlandsNLD
  • Phone+31 205977777
  • Fax+31 205977220
  • Websitehttps://www.philips.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PHIA:AEX since
announced
Transaction
value
Vesper Holdings LLCAnnounced14 Dec 202114 Dec 2021Announced-52.94%--
Vesper Medical IncAnnounced14 Dec 202114 Dec 2021Announced-52.94%--
Data delayed at least 15 minutes, as of Nov 29 2022 15:45 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ambu A/S597.62m12.51m2.52bn4.41k226.155.0148.894.220.37160.371617.5316.770.68611.926.151,007,938.001.445.081.726.2757.4759.902.097.080.932--0.302234.0110.7413.54-62.35-20.9428.54--
Ypsomed Holding AG495.68m32.01m2.65bn2.00k78.395.1124.785.352.432.4337.6137.290.63795.416.20252,988.604.124.976.407.5526.0927.306.467.000.45710.380.249324.1815.163.60297.61-12.9627.27-14.33
GN Store Nord A/S2.36bn90.10m3.15bn8.17k32.693.0310.621.345.225.22136.8056.290.71873.064.892,423,492.002.959.044.3812.2051.4258.314.1111.120.51925.590.691133.6317.2912.7740.2610.0914.206.15
ConvaTec Group PLC2.01bn77.48m5.48bn10.03k70.243.5719.392.730.0330.0330.85480.64850.55863.116.10173,074.502.163.202.533.5954.1154.243.866.310.99372.700.475994.567.603.844.53--6.74--
Getinge AB2.55bn248.05m5.48bn11.11k23.702.1113.222.159.949.94102.00111.800.58292.486.712,589,337.005.733.346.904.4548.6748.069.835.781.4330.710.15140.67-9.294.06-8.3133.59-10.3615.20
Amplifon SpA2.07bn178.28m6.34bn12.59k35.29--15.223.070.79410.76859.22--------164,390.30--4.61--6.1224.7555.818.637.24--9.02--29.1029.5911.4564.6720.1212.6530.01
Demant A/S2.51bn355.69m6.46bn18.13k18.146.12--2.5711.4910.3781.1234.060.73282.055.311,106,131.0010.429.0718.4914.7875.1675.2314.2211.960.587945.490.62120.0023.758.33140.5013.0711.99--
Smith & Nephew plc5.04bn479.79m11.04bn18.00k23.192.1210.592.190.47280.47284.975.170.49560.80754.13237,325.004.726.695.908.0871.0372.549.5112.340.83567.990.349152.9014.302.2216.96-7.740.80335.28
Carl Zeiss Meditec AG1.78bn245.28m11.71bn3.75k47.87--71.796.572.742.7419.87--------504,527.00--8.57--10.5659.1156.5913.8611.34--6.84--36.1523.318.6493.0619.1618.8116.47
Koninklijke Philips NV17.35bn-1.36bn12.44bn79.10k----56.790.7169-1.54-1.5319.63--------221,885.40--3.59--5.0139.7345.57-7.875.64--15.82-----0.9068-0.3072-38.65-5.050.18451.63
Sonova Holding AG3.67bn658.29m15.38bn17.07k23.497.4817.094.1910.5110.5158.7133.000.65962.827.71215,544.1012.0310.5016.1913.5571.1171.8018.2417.470.841230.350.456133.6529.297.0214.2012.581.6513.85
Straumann Holding AG2.26bn497.86m17.77bn9.88k35.819.9629.217.873.053.0513.8410.980.73771.985.03244,616.2016.3212.9119.6315.6276.0475.1622.1218.082.3042.530.29333.3041.8017.12333.9111.5220.979.69
Coloplast A/S3.04bn632.85m23.37bn14.57k39.6922.4730.837.7022.1122.11106.1039.060.8892.516.311,549,479.0018.5327.7325.3442.8768.7868.1220.8422.590.761325.880.692989.1816.237.77-2.474.3910.635.92
Data as of Nov 29 2022. Currency figures normalised to Royal Philips's reporting currency: Euro EUR

Institutional shareholders

24.13%Per cent of shares held by top holders
HolderShares% Held
Artisan Partners LPas of 05 May 202245.37m5.10%
The Vanguard Group, Inc.as of 04 Nov 202223.46m2.64%
Norges Bank Investment Managementas of 31 Dec 202122.03m2.48%
UBS Asset Management (UK) Ltd.as of 18 May 202221.30m2.40%
Wellington Management Co. LLPas of 01 Jul 202219.93m2.24%
DWS Investment GmbHas of 03 Nov 202218.03m2.03%
BlackRock Investment Management LLCas of 24 Nov 202217.62m1.98%
Harris Associates LPas of 30 Sep 202216.75m1.88%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 202215.49m1.74%
BlackRock Fund Advisorsas of 03 Nov 202214.62m1.64%
More ▼
Data from 31 Dec 2021 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.